Clinical Trial Update: A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome [NA]

View source ↗

Summary

The trial evaluating the probiotic Bifidobacterium longum NCC3001 for Irritable Bowel Syndrome has completed. It was sponsored by Société des Produits Nestlé (S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Bifidobacterium longum NCC3001 (Bifidobacterium longum NCC3001)

Snippet

Sponsor: Société des Produits Nestlé (SPN) | Conditions: IBS - Irritable Bowel Syndrome | NA | Status: COMPLETED